Norikazu Harii

Title: Norikazu Harii: Innovator in Autoimmune Disease Treatment

Introduction

Norikazu Harii is a prominent inventor based in Yamanashi, Japan. He has made significant contributions to the field of pharmaceutical sciences, particularly in the treatment of autoimmune and inflammatory diseases. With a focus on innovative therapeutic methods, Harii has been awarded 2 patents for his groundbreaking work.

Latest Patents

Harii's latest patents include the use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor overexpression. His research addresses the treatment of conditions related to Toll-like receptor 3 (TLR3) and Toll-like receptor 4 (TLR4) signaling in nonimmune cells, monocytes, macrophages, and dendritic cells. The patents disclose methods for treating subjects with diseases linked to abnormal TLR signaling and provide pharmaceutical formulations aimed at inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression. Additionally, Harii has developed methods for ameliorating episodes of acute or chronic ulcerative colitis using methimazole derivatives in combination with other pharmaceutical compounds.

Career Highlights

Norikazu Harii is affiliated with Ohio University, where he continues to advance his research in the pharmaceutical field. His work has garnered attention for its potential to improve treatment options for patients suffering from autoimmune and inflammatory diseases.

Collaborations

Harii has collaborated with notable colleagues, including Leonard D Kohn and Douglas Goetz, to further enhance the impact of his research and innovations.

Conclusion

Norikazu Harii's contributions to the treatment of autoimmune diseases through innovative pharmaceutical methods highlight his role as a leading inventor in the field. His patents reflect a commitment to advancing medical science and improving patient outcomes.